Trulicity autoinjector pens recalled for incorrect strength labeling
Eli Lilly & Company is recalling Trulicity (dulaglutide) 0.75 mg autoinjector pens because some contain double the labeled strength. Affected patients may receive an incorrect dose.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall involving a prescription drug with a significant dosing error (100% overdose). Incorrect drug dosing poses a substantial risk of adverse health consequences, including potential hospitalization. The hazard is not theoretical—patients receiving double the prescribed dose face real clinical risk.
Plain-English summary
Eli Lilly & Company is recalling Trulicity (dulaglutide) autoinjector pens due to a labeling error. The pens are labeled as containing 0.75 mg / 0.5 mL, but actually contain 1.5 mg / 0.5 mL of product—double the declared strength.
The affected product is Trulicity (dulaglutide), 0.75 mg/0.5 mL, 4 Single-Dose Pens per box (NDC 0002-1433-80), lot number D396436C. Approximately 119,539 4-packs were distributed nationwide in the USA.
Patients using these pens may administer a higher dose than prescribed, which could result in unintended health effects. Trulicity is a prescription medication used to treat type 2 diabetes. Consumers who have this lot should contact their healthcare provider or pharmacist immediately for guidance. Patients should not stop taking their diabetes medication without consulting their doctor.
The recalled product
- Product
- TRULICITY (DULAGLUTIDE)
- Brand
- TRULICITY
- Manufacturer
- Eli Lilly & Company
- Hazard
- dose-overdose
- labeling-error
- strength-mislabeling
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot number: D396436C
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · TRULICITY
- HighTRULICITY Dulaglutide Injection Recalled for Temperature Abuse During Distribution
FDA (Drugs) · 2022-05-25
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27